









Haddon Heights Office
713 Station Avenue
Haddon Heights, N.J. 08035
Phone
856-547-8004
Fax
856-547-8377
Hammonton Office
8 N. White Horse Pike
Suite 101
Hammonton, N.J. 08037
Phone
609-567-1440
Board Certified in Rheumatology & Fellow of the American College of Rheumatology


MARK FISHER, M.D., F.A.C.R.
DIPLOMATE, AMERICAN BOARD OF INTERNAL MEDICINE
DIPLOMATE, AMERICAN BOARD OF
INTERNAL MEDICINE SUBSPECIALTY-RHEUMATOLOGY
Education:
1965 – 1969
Rutgers University, New Brunswick, New Jersey B.A. Degree in Biological Sciences
1969 – 1973
Hahnemann Medical College, Philadelphia, Pennsylvania Doctor of Medicine, M.D., Honors in Medicine
1973 – 1974
Hahnemann Hospital, Philadelphia, Pennsylvania Straight Medical Internship
1974 – 1976
Hahnemann Hospital, Philadelphia, Pennsylvania Residency, Internal Medicine
1976 - 1978
Temple University Hospital, Philadelphia, Pennsylvania Fellowship in Rheumatology
Postgraduate Courses:
Review Course in Rheumatology, American College of Rheumatology 1978, 1980,1983, 1987, 1990, 2000, 2003
Immunology for the Non-Immunologist
Harvard Medical School, 1977
Course in Metabolic Bone Disease
Peter B. Brigham Hospital, Harvard Medical School, 1977
N.Y.U. Seminar in Advanced Rheumatology
N.Y.U., New York City, New York 1977, 1983, 1986, 1989, 1991, 1993, 1997, 2002,2004
Annual Seminars
New Jersey and Philadelphia Rheumatism Societies American College of Rheumatology 1978, 1980, 1983, 1987, 1990, 2000, and 2003.
Southeastern Regional Meeting 1991
American College of Rheumatology
Postgraduate Course in Rheumatology
University of Pennsylvania, Philadelphia, Pennsylvania 1989, 1990, 1991, 1992, 1993 and 2003
Academic Affiliations:
1979 - Present
Clinical Assistant Professor of Medicine
Thomas Jefferson University Hospital, Philadelphia, PA
1978 - 1984
Coordinator of Junior Medical Student Program in Medicine
1978 - 1979
Our Lady of Lourdes Medical Center, Camden, New Jersey
1976 - 1978
Assistant Professor of Medicine
Hahnemann Hospital, Philadelphia, Pennsylvania
Instructor in Medicine
Temple University Hospital, Philadelphia, Pennsylvania
Teaching/Administrative Appointments:
1997 – 1998
Clinical Studies, New Jersey
1990 - Present
Chief, Division of Rheumatology
Kessler Memorial Hospital, Hammonton, New Jersey
1979 - 1987
Director of Outpatient Arthritis Services
Our Lady of Lourdes Medical Center, Camden, New Jersey
1985 – 2004
Consultant in Rheumatology
Cooper Hospital/University Medical Center, Camden, NJ
1978 - 1984
Coordinator of Junior Medical Student Program in Medicine Our Lady of Lourdes Medical Center, Camden, New Jersey
1980 - Present
Consultant in Rheumatology
Kessler Memorial Hospital, Hammonton, New Jersey
1978 - Present
Private Practice, The Wellness Center at Haddon 713 Station Avenue, Haddon Heights, NJ 08035
1979 - Present
Clinical Assistant Professor of Medicine
Thomas Jefferson University Hospital, Philadelphia, PA
1979 – Present
Chief, Division of Rheumatology
Our Lady of Lourdes Medical Center, Camden, New Jersey
1978 - 1979
Assistant Professor of Medicine
Hahnemann Hospital, Philadelphia, Pennsylvania
1980 - Present
Private Practice; Midway Professional Center, Suite 101 8 North White Horse Pike, Hammonton, NJ 08037
1976 - 1978
Instructor in Medicine
Temple University Hospital, Philadelphia, Pennsylvania
Professional Memberships/Organizations:
American Medical Association
Camden County Medical Society
New Jersey State Medical Society
Philadelphia Rheumatism Society
New Jersey Rheumatism Society
American College of Rheumatology
American College of Physicians American Society of Internal Medicine
International Society Clinical Densitometry
National Osteoporosis Foundation
Licenses/Certifications:
Active
1974 New Jersey - MA29067
1974 Pennsylvania - MD015488-E
1974 Diplomat of the National Board of Medical Examiners
1976 Diplomat of the American Board of Internal Medicine, #54888
1984 Diplomat of the American Board of Internal Medicine,
Subspecialty Rheumatology, #54888
2000 Certified Clinical Densitometry, International Society
Clinical Densitometry
Current Hospital Staff Appointments:
1978 - Present
Our Lady of Lourdes Medical Center, Camden, New Jersey Attending Physician
1980 - Present
Kessler Memorial Hospital, Hammonton, New Jersey Consultant in Rheumatology
1985 – 2004
Cooper Hospital/University Medical Center, Camden, New Jersey Consultant in Rheumatology
Research Experience:
SB-767905/011:
Double-Blind, Placebo-Controlled, Multicenter Phase IIB Study to Evaluate Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects with Chronic Pain.
ABD104225:
Prospective, Observational Study, to Characterize GI Function and Morbidity, and the Humanistic Burden of Illness Among Opioid-Naïve Subjects With Pain Treated With Opioid Therapy.
Voltar Study:
Twelve patients were enrolled for a Phase III clinical trial of Voltaren, a new
NSAID.
Nabumetone Study:
Study comparing a new NSAID, Nabumetone, to another NSAID in a Phase III
clinical trial.
Treazolam and Temazepam:
Insomnia treatment study, comparing Treazolam and Temazepam.
Mucosa Trial:
Double blind study evaluating Cytotec plus NSAID and the risk of GI
complications.
Ultram Study:
Randomized study comparing Ultram to NSAID and narcotic analgesics for pain.
Rheumatoid Arthritis Study:
A double blind, randomized, parallel group, multicenter comparison of the efficacy and safety of Mycophenolate mofetil p.o. (Xg b.i.d.) and placebo in patients with active rheumatoid arthritis (six month efficacy study) who are candidates for immunosuppressive therapy for rheumatoid arthritis.
Meloxicam Study:
A multicenter, double blind, double dummy, randomized, parallel group trial to compare the efficacy and safety of three doses of Meloxicam (X, X and Xmg) with XXX (X mg) and placebo in patients with osteoarthritis.
Meloxicam Study:
A multicenter, double blind, double dummy, randomized, parallel group trial to compare the efficacy and safety of three doses of Meloxicam with Naproxen and placebo on patients with rheumatoid arthritis.
Rofecoxib Study:
Randomized double blind multicenter study evaluating the tolerability and
effectiveness of Rofecoxib versus Naproxen in patients with rheumatoid arthritis.
Rofecoxib Study:
Randomized double blind multicenter study evaluating the tolerability and
effectiveness of Rofecoxib versus Naproxen in patients with osteoarthritis.
Naltrexone HCI
A multicenter, Randomized, Double-Blind, Active-and Placebo-Controlled, Phase lll, Effacacy and Safety Study of Oxycodone HCI and Low-Dose Naltrexone HCI( in Patients with Moderate to Severe Chronic Pain due to Osteoarthritis of the Hip or Knee.
Diclofenac Sodium Gel
Randomized, double-blind multi-centered, vehicle-controlled, parallel group study to assess the efficacy and safety of the Diclofenac Sodium Gel 1%
For the relief of signs and symptoms in patients with osteoarthritis of the knee.
DOV-075-020-US
Double blind, placebo-controlled randomized study of Bicifadine in the treatment of Chronic Low Back Pain
MK0663
A Randomized Double Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients with Osteoarthritis and Rhematoid Arthritis.
MK-0663
A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib vs. Diclofenac Sodium in Patients with Rheumatoid Arthritis.
MK-0663
26 Week Randomized, Placebo-and Active-Comparator-Controlled, Parallel-Group, Double-Blind, 2 Part study to Assess the Safety and Effacacy of Etoricoxib vs Celecoxib in Patients with Osteoarthritis.
RADIUS 1 Study
Rheumatoid Arthritis DMARD Intervention and UtilizationStudy.
OXY4003 STUDY
Multicenter Usual Care Open-Labeled Randomized-Parallel-Group Trial Comparing the Impact of Therapy with Oxycontin vs. Usual Care in Moderate to Severe Osteoarthritis of the Hip or Knee.
SB-767905/011
Double-Blind, Placebo-Controlled, Multicenter Phase IIB Study to Evaluate Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects with Chronic Pain.
ABD104225
Prospective, Observational Study, to Characterize GI Function and Morbidity, and the Humanistic Burden of Illness Among Opioid-Naïve Subjects With Pain Treated With Opioid Therapy.
PTI-801-XH
A Multi-center, Randomized, Double-Blind, Active- and Placebo-Controlled, Phaselll, Efficacy and Safety Study of Oxycodone HCI and Low Dose Naltrexone HCI in Patients With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Hip or Knee.
VOSG-PN-310
A 12 Week, Randomized, Double-Blind, Multicenter, Vehicle-Controlled, Parallel Group To Assess the Efficacy and Safety of the Diclofenic Sodium Gel 1% for the Relief of Signs and Symptoms in Patients with Osteoarthritis of the Knee.
SB/767905-012/014
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Effacacy and Safety of Alvimopan for 12 Weeks and 12 Months for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain.
MDT3-005
A Two-Arm study Comparing the Analgesic Efficacy and Safety of Tramadol HCI Once-a-Day Versus Placebo for the Treatment of Pain Due to Osteoarthritis.
WA 18063B
A randomized, double blind placebo controlled parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo in combination with traditional DMARD therapy in patients with moderate to severe
active rheumatoid arthritis and an inadequate response to current DMARD therapy.
B3D-US-GHCQ:
Direct assessment of non vertebral fractures in community experience (DANCE).
P-AD452-0fl:
A Phase II randomized, double-blind, multicenter, placebo controlled, dose ranging parallel group study to compare the efficacy, safety and tolerability of three strengths of AD 452 in adult subjects with active rheumatoid arthritis who are currently
taking Methotrexate.
WA18696:
2005 Long term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA core\ studies.
U384g:
2006 A phase three, randomized, double blind, placebo controlled, multi center study of re-treatment with Rituxirnab in subjects with rheumatoid arthritis receiving background methotrexate.
WA17824:
2006 A randomized, double blind, double dummy, parallel group study of the safety and efficacy of MRA monotherapy, vs methotrexate monotherapy, in patients with active rheumatoid arthritis.
MLN-MD-03:
2006 A phase three pivotal, multi center, double blind, randomized, placebo controlled monotherapy study of Milnacipran for the treatment of fibromyalgia.
ACT 3986G
Randomized double-blind parallel group to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active RA who have an inadequate response to at least one anti- TNF -therapy.
ACT 3985G
Phase 111 study investigating two dose regimens of rituximab, two infusions of either 500 or 1000 mg separated by 14 days between treatments in patients with RA unresponsive to Methotrexate or patients naive to methotrexatc.
U3924G
Open label study of the safety of Rituximab in combination with other disease modifying anti-rheumatic drugs is subjects with active Rheumatoid Arthritis.
R331333-PAI-3011
Randomized double-blind, placebo-and active-controlled parallel arm phase 111 trial with controlled adjustment of dose to evaluate the efficacy and safety ofCG5503 Extended-Release in subjects with Moderate to Severe Chronic Low Back Pain.
If you have any questions, pelase call 856-547-8004 Ext: 13